TICKERNERD
Menu
ACRSACRSHealthcare · Biotechnology

ACRS Stock Forecast: Aclaris Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$6.41
+1.26% on the day

The 11 Wall Street analysts covering Aclaris Therapeutics, Inc. hold a median 12-month price target of $10 — +56.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$943.5M
Ticker Nerd rank
65 / 100
Median analyst target
$10
Analysts covering
11
Total return, dividends reinvested
1W
+10.9%
1M
+12.7%
YTD
+113.0%
1Y
+266.3%
From 52W high
−0.5%
From 52W low
+266.3%
$1.75
$6.44
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACRS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aclaris Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Value
68
Revisions
64
Growth
55
Accruals
49
Size
46
Volatility
45
Quality
44
Issuance
39

Momentum (100): The shares have been drifting up relative to others.

Issuance (39): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACRS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACRS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26ACRSHigh $16Median $10Low $4

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
10 Buy1 Hold0 Sell
Low $4Median $10High $16

The green dot is the last close — the median target sits +56.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 June 2026LifeSci CapitalInitiatesOutperform$13
5 May 2026GuggenheimInitiatesBuy—
5 May 2026Piper SandlerMaintainsOverweight—
29 Apr 2026WedbushMaintainsOutperform—
16 Apr 2026OppenheimerInitiatesOutperform—
31 Mar 2026WedbushReiteratesOutperform—
19 Mar 2026HC Wainwright & Co.ReiteratesBuy—
28 Jan 2026HC Wainwright & Co.ReiteratesBuy—
21 Jan 2026HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
10 July 2025Piper SandlerAssumesOverweight$6.00
25 June 2025HC Wainwright & Co.ReiteratesBuy—
28 May 2025WedbushInitiatesOutperform—
14 May 2025HC Wainwright & Co.MaintainsBuy—
9 May 2025ScotiabankMaintainsSector Outperform—
18 Mar 2025Cantor FitzgeraldReiteratesOverweight—
7 Mar 2025ScotiabankInitiatesSector Outperform—
23 Dec 2024HC Wainwright & Co.UpgradeBuy—
19 Nov 2024BTIGUpgradeBuy—
19 Nov 2024JefferiesUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACRS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ACRS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Aclaris Therapeutics, Inc. (ACRS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.1×

Cheaper than 94% of US stocks

Price / sales
114.8×

Cheaper than 4% of US stocks

Price / book
7.2×

Cheaper than 15% of US stocks

EV / EBITDA
−9.8×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
−8.3%

Higher than 17% of US stocks

Earnings growth (YoY)
−8.3%

Higher than 27% of US stocks

Gross margin
10.8%

Higher than 10% of US stocks

Operating margin
−1469.5%

Higher than 5% of US stocks

Net margin
6.9%

Higher than 64% of US stocks

Returns & dividend
Return on equity
−59.1%

Higher than 19% of US stocks

Return on assets
−29.0%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ACRS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACRSAclaris Therapeutics, Inc.$943.5M
65
ARDXArdelyx, Inc.$945.2M
55
OLMAOlema Pharmaceuticals, Inc.$931.7M
29
ANNXAnnexon, Inc.$961.2M
37
CADLCandel Therapeutics, Inc.$961.7M
44
DSGNDesign Therapeutics, Inc.$924.5M
66
IMMXImmix Biopharma, Inc.$972.5M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aclaris Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACRS news & analysis

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

Zacks Investment Research · 10 Aug 2026positive

The consensus price target for Aclaris (ACRS) implies a potential 69.2% upside, although the article notes this metric is of limited effectiveness. It also flags that an upward trend in earnings estimate revisions could indicate near-term upside for the stock.

Why it matters — ACRS watchers would care because the report highlights both bullish estimate-revision momentum and a consensus price target implying significant upside, offering signals about how analysts view the stock's near-term prospects.

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

GlobeNewsWire · 6 Aug 2026positive

Aclaris Therapeutics announced that the FDA granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus, including oral erosive LP, cutaneous LP, and lichen planopilaris. The company expects to initiate a phased multi-part Phase 2b trial of modzatinib in LP in the fourth quarter of 2026.

Why it matters — Fast Track designation for modzatinib signals potential expedited development and review for a key pipeline candidate, relevant to Aclaris watchers tracking the company's immuno-inflammatory disease programs.

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Aclaris Therapeutics reported a Q2 loss of $0.15 per share, which was narrower than the Zacks Consensus Estimate of a $0.16 loss but wider than the $0.13 per-share loss a year ago. The report indicates the company topped revenue estimates.

Why it matters — ACRS watchers would care because the quarterly loss came in better than analysts expected, even though it was larger than the prior-year loss.

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

GlobeNewsWire · 6 Aug 2026positive

Aclaris Therapeutics announced its second quarter 2026 financial results and provided a corporate and clinical update. The company reported full top-line results from the Phase 1a SAD/MAD trial of ATI-052, validating a potential best-in-class potency advantage and opportunity for extended dosing, reaffirmed timelines for upcoming top-line results from Phase 1b proof-of-concept trials of ATI-052 and the Phase 2 trial of Bosakitug (ATI-045), and stated its cash runway is expected to support pipeline development through the end of 2028.

Why it matters — ACRS watchers would follow this update because it provides validation of ATI-052's potency, reconfirms clinical trial readout timelines for key pipeline candidates, and signals financial runway through 2028.

FAQ

Frequently asked questions about ACRS stock

What is the ACRS stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Aclaris Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $4 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACRS stock a buy right now?

Of the 11 analysts covering Aclaris Therapeutics, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aclaris Therapeutics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACRS?

As at 22 Aug 2026, Aclaris Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will ACRS stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +56.0% from the last close, and Ticker Nerd's factor model ranks Aclaris Therapeutics, Inc. 65 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACRS stock forecast for 2030?

No analyst covering Aclaris Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $16 over the next 12 months.

How has ACRS stock performed over the past year?

Aclaris Therapeutics, Inc. returned +266.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aclaris Therapeutics, Inc. do?

Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases.

What is the latest news on ACRS?

The most recent item we track (Zacks Investment Research, 10 Aug 2026): "Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade". The consensus price target for Aclaris (ACRS) implies a potential 69.2% upside, although the article notes this metric is of limited effectiveness. It also flags that an upward trend in earnings estimate revisions could indicate near-term upside for the stock.

Company

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. It operates through two segments: Therapeutics, which identifies and advances innovative therapies to meet unmet needs in conditions such as atopic dermatitis, asthma, and alopecia areata, and Contract Research, which provides laboratory services. Key product candidates include ATI-2138, a potent and selective oral ITK/JAK3 inhibitor demonstrating efficacy in clinical trials for atopic dermatitis and preclinical hair regrowth in alopecia areata models; ATI-052, a bispecific anti-TSLP/IL-4Rα antibody advancing in Phase 1b proof-of-concept trials for atopic dermatitis and asthma with favorable safety, pharmacokinetics, and pharmacodynamics; bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2 trials for moderate-to-severe atopic dermatitis; and others like zunsemetinib and lepzacitinib. Aclaris Therapeutics Inc. targets immune-inflammatory disorders lacking satisfactory treatments, contributing to advancements in immunology through its oral kinase inhibitors and biologics franchises. Founded in 2012 and headquartered in Wayne, Pennsylvania, it plays a role in the biotechnology sector by progressing multiple candidates through clinical development.

CEO Dr. Neal S. Walker D.O., M.D. · 69 employees · United States · https://www.aclaristx.com